Comparison of the mutation spectrum and association with pre and post treatment lipid measures of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries

FUTEMA, M., U. RAMASWAMI, Lukas TICHY, M. P. BOGSRUD, K. B. HOLVEN, J. R. VAN LENNEP, A. WIEGMAN, OS DESCAMPS, A. DE LEENER, E. FASTRE, Michal VRABLIK, Tomáš FREIBERGER, H. ESTERBAUER, H. DIEPLINGER, S. GREBER-PLATZER, A. M. MEDEIROS, M. BOURBON, V. MOLLAKI, E. DROGARI a S. E. HUMPHRIES. Comparison of the mutation spectrum and association with pre and post treatment lipid measures of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries. Atherosclerosis. Clare: ELSEVIER SCI IRELAND LTD, 2021, roč. 319, FEB 2021, s. 108-117. ISSN 0021-9150. Dostupné z: https://dx.doi.org/10.1016/j.atherosclerosis.2021.01.008.

Základní údaje

• Originální název: Comparison of the mutation spectrum and association with pre and post treatment lipid measures of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries
• Autoři: FUTEMA, M., U. RAMASWAMI, Lukas TICHY (203 Česká republika), M. P. BOGSRUD, K. B. HOLVEN, J. R. VAN LENNEP, A. WIEGMAN, OS DESCAMPS, A. DE LEENER, E. FASTRE, Michal VRABLIK (203 Česká republika), Tomáš FREIBERGER (203 Česká republika, domácí), H. ESTERBAUER, H. DIEPLINGER, S. GREBER-PLATZER, A. M. MEDEIROS, M. BOURBON, V. MOLLAKI, E. DROGARI a S. E. HUMPHRIES (garant).
• Vydání: Atherosclerosis, Clare, ELSEVIER SCI IRELAND LTD, 2021, 0021-9150.

Další údaje

• Originální jazyk: angličtina
• Typ výsledku: Článek v odborném periodiku
• Obor: 30201 Cardiac and Cardiovascular systems
• Stát vydavatele: Irsko
• Utajení: není předmětem státního či obchodního tajemství
• WWW: URL
• Impakt faktor: Impact factor: 6.847
• Kód RIV: RIV/00216224:14110/21:00121357
• Organizační jednotka: Lékařská fakulta
• Doi: http://dx.doi.org/10.1016/j.atherosclerosis.2021.01.008
• UT WoS: 000617764400004
• Klíčová slova anglicky: Heterozygous familial hypercholesterolaemia; Mutation spectrum; LDL-C concentrations; Statin treatment
• Štítky: 14110114, rivok
• Příznaky: Mezinárodní význam, Recenzováno

Anotace

Background and aims: Familial hypercholesterolaemia (FH) is commonly caused by mutations in the LDLR, APOB or PCSK9 genes, with untreated mean low density lipoprotein-cholesterol (LDL-C) concentrations being elevated in APOB mutation carriers, even higher in LDLR mutation and highest in those with a PCSK9 mutation. Here we examine this in children with FH from Norway, UK, The Netherlands, Belgium, Czech Republic, Austria, Portugal and Greece. Methods: Differences in characteristics and preand post-treatment lipid concentrations in those with different molecular causes were compared by standard statistical tests. Results: Data were obtained from 2866 children, of whom 2531 (88%) carried a reported LDLR/APOB/PCSK9 variant. In all countries, the most common cause of FH was an LDLR mutation (79% of children, 297 different), but the prevalence of the APOB p.(Arg3527Gln) mutation varied significantly (ranging from 0% in Greece to 39% in Czech Republic, p < 2.2 x 10(-16)). The prevalence of a family history of premature CHD was significantly higher in children with an LDLR vs APOB mutation (16% vs 7% p=0.0005). Compared to the LDLR mutation group, mean (+/- SD) concentrations of pre-treatment LDL-C were significantly lower in those with an APOB mutation (n = 2260 vs n = 264, 4.96 (1.08)mmol/l vs 5.88 (1.41)mmol/l, p < 2.2 x 10(-16)) and lowest in those with a PCSK9 mutation (n = 7, 4.71 (1.22)mmol/l). Conclusions: The most common cause of FH in children from eight European countries was an LDLR mutation, with the prevalence of the APOB p.(Arg3527Gln) mutation varying significantly across countries. In children, LDLR-FH is associated with higher concentrations of LDL-C and family history of CHD compared to those with APOB-FH.